INFLUENZA VIRUS STRAIN A/17/PEKING/95/25 (H1N1) FOR PRODUCTION OF LIVE INFLUENZAL INTRANASAL VACCINE FOR ADULTS

摘要

applied microbiology. SUBSTANCE: vaccinal strain A/17/Peking/95/25 (H1N1), which is reassortant, is obtained by cross-breeding of epidemic virus A/Peking/262/95 (H1N1) with cold-adapted temperature-sensitive virus A/Leningrad/134/47/57 (H2N2), which is attenuation donor. The strain is harmless for adults. It actively multiplies in developing chicken embryos at optimal temperature 33-34 C and is characterized by temperature sensitivity and cold adaptability. Reassortant inherits two genes from epidemic virus, which encode surface proteins (gemmagglutinin and neuraminidase). Six genes received from attenuation donor encode non-glycosylated proteins. The strain does non induce immune response in adults during intranasal injection. Biological properties and low degree of immunoreactivity meet Pharmacopoeia requirements for vaccine strains of live influenzal vaccine for intranasal administration for adults. EFFECT: reliably enabled isolation of reassorted vaccinal strains from newly appearing epidemic viruses. 1 tbl